» Articles » PMID: 21619964

Diffusion-weighted Imaging is Superior to Positron Emission Tomography in the Detection and Nodal Assessment of Lung Cancers

Overview
Journal Ann Thorac Surg
Publisher Elsevier
Date 2011 May 31
PMID 21619964
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Diffusion-weighted magnetic resonance imaging (DWI) makes it possible to detect malignant tumors based on the difference in the diffusion of water molecules among tissues. The aims of this study are to examine the usefulness of DWI compared with positron emission tomography-computed tomography (PET-CT) in the assessment of lung cancer, and the relationships between the apparent diffusion coefficient (ADC) value and several pathologic factors.

Methods: Sixty-three patients with primary non-small cell lung cancer were enrolled in this study. The DWI and PET-CT were performed before surgery. There were 42 adenocarcinomas, 19 squamous cell carcinomas, and 2 other cell types.

Results: Sixty-one lung cancers (97%) were detected visually with DWI. This was significantly higher than 54 lung cancers (86%) with PET-CT. The accuracy for N staging by DWI was 0.81 (51 of 63), which was not significantly higher than 0.71 (45 of 63) by PET-CT. The sensitivity (0.75) for individual metastatic lymph node stations by DWI was significantly higher than that (0.48) by PET-CT. The specificity for individual nonmetastatic lymph node stations was 0.99 by DWI and 0.97 by PET-CT, respectively. The accuracy (0.95) for the diagnosis of lymph node stations by DWI was significantly higher than that (0.90) by PET-CT. There was a weak reverse relationship (correlation coefficient: 0.286) between the ADC value and the maximum standardized uptake value, but no relationship between ADC value and tumor size. The ADC values increased while the cell differentiation increased.

Conclusions: Diffusion-weighted magnetic resonance imaging is superior to PET-CT in the detection of primary lesions and nodal assessment of non-small cell lung cancers.

Citing Articles

Measurements of target volumes and organs at risk using DW‑MRI in patients with central lung cancer accompanied with atelectasis.

Zhang X, Liu T, Zhang H, Zhang M Mol Clin Oncol. 2023; 18(6):45.

PMID: 37152713 PMC: 10155240. DOI: 10.3892/mco.2023.2641.


State of the Art MR Imaging for Lung Cancer TNM Stage Evaluation.

Ohno Y, Ozawa Y, Koyama H, Yoshikawa T, Takenaka D, Nagata H Cancers (Basel). 2023; 15(3).

PMID: 36765907 PMC: 9913625. DOI: 10.3390/cancers15030950.


MRI VS. FDG-PET for diagnosis of response to neoadjuvant therapy in patients with locally advanced rectal cancer.

Gao P, Lu N, Liu W Front Oncol. 2023; 13:1031581.

PMID: 36741013 PMC: 9890074. DOI: 10.3389/fonc.2023.1031581.


Correlation between apparent diffusion coefficient and Ki-67 in different pathological types of lung cancer.

Ren H, Ma J, Wang J Transl Cancer Res. 2022; 10(12):5364-5371.

PMID: 35116383 PMC: 8798236. DOI: 10.21037/tcr-21-2515.


Pulmonary Nodule and Mass: Superiority of MRI of Diffusion-Weighted Imaging and T2-Weighted Imaging to FDG-PET/CT.

Usuda K, Ishikawa M, Iwai S, Yamagata A, Iijima Y, Motono N Cancers (Basel). 2021; 13(20).

PMID: 34680313 PMC: 8533899. DOI: 10.3390/cancers13205166.